Impact of tDCS on Cannabis Craving in Schizophrenia
NCT05784961, Not applicable, Not yet recruiting, Centre hospitalier de Ville-Evrard, France
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Impact of tDCS on Cannabis Craving in Schizophrenia | ClinicalTrials.gov |
| NCT number | NCT05784961 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 138 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Centre hospitalier de Ville-Evrard, France | ClinicalTrials.gov |
| Conditions | Schizophrenia, Cannabis Use Disorder | ClinicalTrials.gov |
| Interventions | tDCS | ClinicalTrials.gov |
| First posted | 2023-03-27 | ClinicalTrials.gov |
| Last updated | 2024-02-16 | ClinicalTrials.gov |
Registered outcomes 13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change in Marijuana Craving Questionnaire (MCQ) | At baseline (Visit 2) and Day 5 (Visit 6) | To asses variation in cannabis craving state. The minimum value is 9 and the maximum value is 63. | ClinicalTrials.gov |
| Secondary | Change in Score of the PANSS (Positive and Negative Syndrome Scale) to assess the psychopathology of schizophrenia | At baseline (Visit 2) and Day 2, Day 5 (Visit 6), 5 weeks (Visit 7), 13 weeks (Visit 8) | assessment of schizophrenia psychopathology. The minimum value is 7 and the maximum value is 49 for positive scale and negative scale. For general psychopathology, the minimum value is 16 and the maximum value is 112. | ClinicalTrials.gov |
| Secondary | Change in Score of SNS (schizophrenia negative symptoms) to assess negative symptoms | At baseline (Visit 2) and , Day 5 (Visit 6), 5 weeks (Visit 7), 13 weeks (Visit 8) | Assessment of schizophrenia negative symptoms. The total score is the sum of the 20 items, ranging from 0 (no negative symptoms) to 40 (severe negative symptoms). | ClinicalTrials.gov |
| Secondary | Change in Score of CGI (Clinical Global Impression) to clinical outcome | At baseline (Visit 2) and, Day 5 (Visit 6), 5 weeks (Visit 7), 13 weeks (Visit 8) | CGI scale assess clinical outcome | ClinicalTrials.gov |
| Secondary | Change in VAS score (visual analog scale) to assess the craving to cannabis | At baseline (Visit 2) and Day 2 (Visit 3), Day 3 (Visit 4),Day 4 (Visit 5), Day 5 (Visit 6), 5 weeks (Visit 7), 13 weeks (Visit 8) | Cannabis craving status assessment. It is a ruler from 0 to 10 : 0 = absence of craving, 1-3 = low craving, 4-6 = moderate craving, 7-9 = intense craving, 10 = extreme craving. | ClinicalTrials.gov |
| Secondary | Change in VAS score (visual analog scale) to assessed the craving to nicotine | At baseline (Visit 2) and Day 2 (Visit 3), Day 3 (Visit 4),Day 4 (Visit 5), Day 5 (Visit 6), 5 weeks (Visit 7), 13 weeks (Visit 8) | Nicotine craving status assessment. It is a ruler from 0 to 10 : 0 = absence of craving, 1-3 = low craving, 4-6 = moderate craving, 7-9 = intense craving, 10 = extreme craving. | ClinicalTrials.gov |
| Secondary | Change in BART Analogue Risk Task score | At baseline (Visit 2) and Day 5 (V6) | BART Analogue Risk assesses risk taking behavior | ClinicalTrials.gov |
| Secondary | change in STROOP Test score | At baseline (Visit 2) and Day 5 (V6) | Stroop test assesses continuous attention and inhibition abilities | ClinicalTrials.gov |
| Secondary | Change in Exhaled carbon monoxide concentration score | At baseline (Visit 2) and Day 5 (V6) | concentration assessment of monoxide de concentration | ClinicalTrials.gov |
| Secondary | Urinary cannabis test | between baseline (Visit 2), Day 5 (Visit 6), 5 weeks (Visit 7), 13 weeks (Visit 8) | assessemnt of cannabis presence in urine | ClinicalTrials.gov |
| Secondary | Cannabis and tobacco use assessement | At baseline (Visit 2), Day 5 (V6), 5 weeks (V7) and 13 weeks (V8) | Assessment of actual use of cannabis and tobacco (numbers of cigarettes, number of joints | ClinicalTrials.gov |
| Secondary | Score to Big Five to assessed the personnality dimensions | Baseline (Visit 2) | The "Big Five" model or the big five personality factors is a tool for personality assessment : extraversion (E), agreeableness (A), conscientiousness (C), neuroticism (N) and openness (O).It is a taxonomic system that measures personality traits. The Bige Five consists of 44 items which are rated on a five-point likert scale from 1 (disagree a lot) to 5 (agree a lot). | ClinicalTrials.gov |
| Secondary | Change in MCQ (Marijuana Craving Questionnaire) | At baseline (Visit 2), (Visite 6),(Visit 7) and 13 weeks (Visite 8) | The minimum value is 9 and the maximum value is 63. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)